We evaluated whether exercised-based cardiac rehabilitation (CR) can ameliorate the HDL function, i.e., cholesterol efflux capacity (CEC) and paraoxonase-1 activity in patients with acute coronary syndrome (ACS). Methods: This study is a retrospective analysis of stored serum from patients with ACS following successful percutaneous coronary intervention. The CEC, measured by a cell-based ex vivo assay using apolipoprotein B-depleted serum and 3 H-cholesterol labeled macrophages and arylesterase activity (AREA) at the onset or early phase of ACS, and the follow-up periods were compared between 69 patients who completed the five-month outpatient CR program (CR group) and 15 patients who did not participate and/or dropped out from CR program (non-CR group). Results: Apolipoprotein A-I (apoA-I) and CEC significantly increased by 4.0% and 9.4%, respectively, in the CR group, whereas HDL-cholesterol and AREA were not changed during the follow-up periods in both groups. Among CR patients, the CEC significantly increased, irrespective of the different statin treatment, while HDL-cholesterol and apoA-I significantly increased in patients treated with rosuvastatin or pitavastatin. Although CEC and AREA were significantly correlated each other, there is a discordance between CEC and AREA for their correlations with other biomarkers. Both CEC and AREA were significantly correlated with apoA-I rather than HDL-cholesterol. Changes in CEC and those in AREA were significantly correlated with those in apoA-I (rho = 0.328, p = 0.002, and rho=0.428, p＜0.0001, respectively) greater than those in HDL-cholesterol (rho = 0.312, p = 0.0042, and rho=0.343, p=0.003, respectively). Conclusions: CR can improve HDL function, and it is beneficial for secondary prevention.
atherosclerotic cardiovascular disease 6) . This suggests that altering CEC could be a novel therapeutic approach for the prevention of atherosclerotic cardiovascular disease 7) . Besides CEC, HDL has several other anti-atherogenic properties including antioxidant capacity, antiinflammatory properties, and nitric oxide-promoting activity 1) . Paraoxonase-1 (PON1) is a plasma enzyme that is synthesized in the liver and resides on HDL particles, and has been shown to possess antioxidant properties resulting in the inhibition of the oxidation of low-density lipoprotein (LDL) particles 8) . PON1 hydrolyzes different kinds of substrates and act as paraoxonase to hydrolyze oxons like paraoxon and as arylesterase to hydrolyze aromatic esters like phenylacetate 8) .
It has been reported that low PON1 activities in either paraoxonase activity (PONA) or arylesterase activity (AREA) were significantly associated with elevated risk for CAD 9) . Berrougui et al. showed that PON1 regulates the CEC by enhancing the interaction between apoA-I and ATP-binding cassette A1 (ABC A1) 10) . Comprehensive cardiac rehabilitation (CR) has been shown to be beneficial in improving exercise capacity, quality of life, and/or prolonging survival in patients with CAD 11) . Recent our preliminary study was the first to show that a six-month CR program significantly increased CEC as well as HDL-C and apoA-I in 57 patients with acute coronary syndrome (ACS), whereas those changes were not seen in 11 patients who dropped out from the outpatient CR program; increases in CEC were significantly correlated to increases in HDL-C and apoA-I 12) . It is conceivable that CR may improve PON1 activity as well as CEC. To date, only one observational study reported that a 12-week CR program increased AREA in 37 patients with CAD 13) . In the present study, we investigated the effects of CR on CEC and AREA in patients with ACS.
Methods

Study Patients
The present study enrolled patients with ACS that followed successful percutaneous coronary interventions (PCI) between August 2005 and May 2015, and all of the studied patients were distinct from the patients in our previous study 12) . The diagnoses of ACS were based on electrocardiographic changes and coronary arteriograms. Serum samples were collected immediately before the emergency coronary angiography on admission of ACS and/or in a fasting state at the beginning of the CR program, and unused samples were stored for long-term storage at −80 ℃. The exclusion criteria included severe hepatic disease, end-lipoprotein levels were determined by an immunoturbidimetric assay (Daiichi Chemicals Co. Ltd. Tokyo, Japan). Malondialdehyde-modified LDL (MDA-LDL) was measured using an enzyme-linked immunosorbent assay 20) . Remnant lipoproteins (RLPs) were isolated from the serum to an immunoaffinity mixed gel containing anti-apoA-I and anti-apolipoprotein B 100 (apoB) monoclonal antibodies (Japan Immunoresearch Laboratories, Takasaki, Japan), and the cholesterol concentrations of the unbound fraction were measured as RLP cholesterol (RLP-C) 21) . The high-sensitivity C-reactive protein (hsCRP) level was measured by the Dade Behring BN assay 22) . Plasma brain natriuretic peptide (BNP) was measured by chemiluminescence-enzyme immunoassay.
Measurement of Cholesterol Efflux Capacity (CEC) and Arylesterase Activity (AREA)
Serum samples were kept frozen at −80 ℃ until the assay for CEC and AEA. CEC was performed according to the methods used by Khera et al. [3] [4] [5] 12) . The murine macrophage cell lines J774.1 were purchased from RIKEN (Tsukuba, Japan), cultured in RPMI 1640 medium (Sigma-Aldrich, MO, USA), containing 10% fetal bovine serum, and kept under constant conditions of 5% carbon dioxide and a temperature of 37 ℃. J774.1 cells were plated in 24-well plates, grown to 80 -90% confluence, and radiolabeled with 2 μCi/mL of 3 H-cholesterol. ApoB-depleted serum was prepared by incubation with a 13% polyethylene glycol 6000 solution (Wako Pure Chemicals). Subsequently, an efflux medium containing 2.8% apoBdepleted serum was added and incubated for four hours. All procedures were performed in the presence of the acyl-coenzyme A: cholesterol acyltransferase inhibitor Sandoz 58 -035 (2 μg/mL; Sigma-Aldrich, MO, USA) and 8-bromoadenosine 3´, 5´-cyclic monophosphate (0.3 mmol/L; Sigma-Aldrich, MO, USA). A liquid scintillation counter was used to quantify the efflux of radioactive cholesterol from the supernatants of each well, and the extraction of cell lysates through the equal mixture of hexane and isopropanol in control wells that was not exposed to the serum. CEC was measured by determining the percentage of radiolabeled cholesterol released (% cholesterol efflux) using the following formula: Percent efflux was calculated using the following formula: (cpm of 3 H-cholesterol in media containing 2.8% apoB-depleted serum -cpm of 3 H-cholesterol in serum-free mediums)/(cpm of 3 Hcholesterol in cells extracted before the efflux step)× 100. All assays were performed in duplicate. The CEC of patients' sera were expressed as the relative values to the pooled serum for standardization.
The AREA was measured by using a commerpeak exercise was regarded as peak VO2 and as an indices of exercise capacity. The BP and HR were measured using an oscillometric device (Form/ABI, Colin Company, Ltd., Komaki, Japan) at the beginning of the CR program and at the follow-up period of blood sampling. Four pneumatic pressure cuffs, two electrocardiogram electrodes, and one microphone for detecting heart sounds were attached on both arms and ankles, wrists, and the left edge of the sternum, respectively, to record the volume waveform for the brachial and ankle arteries. The subjects were kept at rest in supine position for at least 5 -10 min. The examination room was maintained at a standardized temperature. The Ankle Brachial Index (ABI) of less than 0.90 was diagnosed with peripheral artery disease (PAD). The diagnosis of hypertension was based on a history of hypertension or BP above 140 mmHg (systolic) or 90 mmHg (diastolic) 15) . Diabetes mellitus (DM) was defined as a fasting serum glucose value greater than 126 mg/dL, HbA1c greater than 6.5%, and/or current use of medication for DM 15) . Dyslipidemia was defined as the current use of lipid-lowering medication and/or meeting the criteria of the Japan Atherosclerosis Society for fasting serum lipid levels as follows: LDL-C ≥ 140 mg/dL, HDL-C ＜40 mg/dL, or triglyceride ≥ 150 mg/dL 15) . A serum creatininebased estimate of glomerular filtration rate (eGFR) was calculated as follows: eGFR = 194×Cr −1.094 ×Age −0.287 (×0.739 for women) 16) . Body mass index (BMI) was calculated as weight (kilograms) divided by height (meters) squared. Patients with a reported smoking habit of at least one cigarette per day on admission were classified as current smokers. Former smokers were defined as having previously smoked but ceased before the onset of ACS.
Targets for the controls of risk factors are smoking cessation, systolic BP ＜140 mmHg 17) , diastolic BP ＜90 mmHg 17) , LDL-C ＜100 mg/dl 15) , non-HDL-C ＜130 mg/dl 15) , HDL-C ≥ 40 mg/dl 15) , triglyceride ＜150 mg/dl 15) , and HbA1c ＜7.0% 15) .
Laboratory Measurement
Total-cholesterol, triglycerides, HDL-C, and glycated hemoglobin (HbA1c) were measured using standard laboratory procedures. HbA1c values that were measured as HbA1c (JDS) till March 31, 2012, were estimated by ( = 1.019×HbA1c [JDS]＋0.3) 18) . The non-HDL cholesterol (non-HDL-C) level was estimated by subtracting the HDL-C concentration from the total-cholesterol concentration. The LDL cholesterol (LDL-C) levels were measured with a direct homogenous assay (Sekisui Medical Co. Ltd. Tokyo, Japan), that was reported to be as accurate for postprandial samples as for fasting samples 19) . Serum apo- 
Results
Clinical Characteristics and Laboratory Findings at Baseline and Follow-up
The clinical characteristics of the subjects are summarized in Table 1 . Fifty-seven men and twelve women completed the five-month outpatient CR program (CR group), and thirteen men and two women unfortunately decided that they did not participate and/or dropped out from CR program (non-CR group). The mean number of CR sessions in CR group was 33.6, whereas that in non-CR group was 2.7. The percentages of patients with hypertension were significantly higher in the CR group, whereas those with dyslipidemia and DM were similar between the two groups. No patients took an alfa-glucosidase inhibitor or pioglitazone during the study period. The HR significantly decreased and BP, both systolic and diastolic, significantly increased during the follow-up period in the CR group, while those did not change in the non-CR group. Twenty percent of patients in the non-CR group and twenty-nine percent of patients in the CR group took statins at the baseline blood sampling. Only one patient in the CR group discontinued the statin before follow-up blood sampling because of mild elevation of serum transaminase and was treated with ezetimibe. Table 2 compares the laboratory findings at baseline and at follow-up. The baseline blood samples were collected at the beginning of CR in six male and one female patient in the CR group. The LDL-C, non-HDL-C, and ApoB significantly decreased at follow-up in both groups, whereas MDA-LDL, RLP-C, hsCRP, and BNP significantly decreased in the CR group alone. The LDL-C, non-HDL-C, tricially available assay kit (Mega Tip San ve Tic Ltd, Turkey). PON1 hydrolyzes phenyl acetate to phenol and acetic acid. The phenol was colorimetrically measured via oxidative coupling with 4-aminoantipyrine and potassium ferricyanide. Non-enzymatic hydrolysis of phenyl acetate was subtracted from total rate of hydrolysis. The molar absorptivity of the colored complex is 4000M −1 cm −1 and one unit of AREA is equal to 1 mmol of phenyl acetate hydrolyzed per liter per min at 37 ℃. The interassay variation coefficient was less than 7%.
Statistics
All statistical analyses were performed using the IBM SPSS Statistics version 23 software package (IBM Institute). Baseline characteristics were compared between CR and non-CR using unpaired t -test for parametric variables and Mann-Whitney U test for non-parametric variables. Categorical variables were compared with chi-square tests. Changes in blood biomarkers between the baseline and the follow-up in two groups were tested with two-way repeated measures analysis of variance (ANOVA). For within-group comparisons, changes in the biomarkers between the baseline and the follow-up were analyzed using paired t -test for parametric variables and Wilcoxon signed rank test for nonparametric variables. Correlation coefficients between two biomarkers were determined by Spearman's rank analyses. All the statistical analyses were two-tailed. P＜0.05 was considered statistically significant. p＜ 0.0001 compared with the baseline by paired t -test. N/A indicates not available. ACE-I = angiotensinconverting enzyme inhibitor; ACS = acute coronary syndrome; ARB = angiotensin Ⅱ type 1 receptor blocker; CABG = coronary artery bypass graft surgery; CR = cardiac rehabilitation; DPP4=dipeptidyl peptidase-4 inhibitor; LV EF=left ventricular ejection fraction by ultrasound Simpson method; MI = myocardial infarction; n-3 PUFA = n-3 polyunsaturated fatty acid; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; UAP = unstable angina pectoris. ( Fig. 2) .
Effects of Medical Treatment and Smoking Cessation on CEC and AREA
There are marked differences in the smoking state and medical treatment at the follow-up periods between the non-CR and CR groups. Significantly more patients could stop smoking in the CR group. Fourteen patients took angiotensin-converting enzyme inhibitor (ACE-I), four patients took ezetimibe, and eight patients took an n-3 polyunsaturated fatty acid (n-3 PUFA) during the follow-up periods in the CRgroup, whereas no patients took these drugs in the non-CR group. The CEC and AREA at baseline and at follow-up were compared between the non-CR and CR groups in patients who did not take any lipid-lowering drugs at baseline, patients who did not smoke at follow-up, and patients who did not take ACE-I, ezetimibe, and/or n-3 PUFA (Supplementary Fig. 1 ). Although AREA did not change in either the non-CR or CR group, the CEC significantly increased in the CR group alone in these subpopulations.
Effects of Risk Factor Control on CEC in Patients with CR
Among CR patients, four patients continued glyceride, ApoB, and RLP-C at follow-up were significantly lower in the CR group than those in the non-CR group. The HDL-C somewhat decreased in the non-CR group, and AREA non-significantly increased in both the non-CR and CR groups. The CEC and apoA-I significantly increased in the CR group alone (Fig. 1) .
Effects of Different Statins on Lipid Levels and CEC in Statin-naïve Patients
It has been reported that HDL-C-elevating effect, CEC, and anti-oxidative action of HDL differ among the types and doses of statins, and that pitavastatin and rosuvastatin have greater HDL-C-and apoA-Ielevating effects than atorvastatin 23) . Table 3 compares the laboratory findings at baseline and at follow-up in patients treated with atorvastatin and rosuvastatin or pitavastatin among patients without prior lipid-lowering treatment at baseline. A marked reduction of LDL-C, non-HDL-C, ApoB, and MDA-LDL was seen in the CR group as opposed to the non-CR group, irrespective of the different statin treatment. The HDL-C and ApoA-I significantly increased in only patients treated with rosuvastatin or pitavastatin in the CR group, while CEC significantly increased in the CR group, irrespective of the different statin treatment HDL cholesterol Apolipoprotein A-1 Cholesterol Efflux Capacity (Fig. 3) .
Correlation Coefficients between CEC or AREA and Other Variables Table 4 shows Spearman correlation coefficients between CEC or AREA at baseline or at follow-up, and each of the counterparts of biomarkers, and those net changes in whole patients, patients who did not take any lipid-lowering drugs at baseline, and patients smoking, and 83%, 97%, and 54% of patients achieved the targets for BP, HbA1c, and all lipid targets, respectively. The peak VO2 at the follow-up CPX in 69 patients was 18.5±4.5 mL/min/kg. Lower cardiopulmonary fitness was defined as less than 19 mL/min/ kg, and this level was as same as our previous report 12) . Significant increases in CEC were seen irrespective of the exercise capacity, and were seen in the patients who achieved risk factor control except all lipid targets p＜0.0001 compared with the baseline by paired t -test. P = pitavastatin; R = rosuvastatin, other abbreviations as in text and Table 2 .
Discussion
The present study confirmed that CR could increase the CEC irrespective of the concomitant of different statins, while the CEC was not changed under non-CR usual medical therapy in patients with ACS. These results are good agreement with our previous report of separate ACS patients 12) . In contrast to our previous report 12) , HDL-C did not increase in CR patients and this was affected by different statin treatment. There are three novel findings in this report. First, increases in CEC were significantly correlated to increases in AREA. Second, both increases in CEC and those in AREA were correlated with those in apoA1 rather than those in HDL-C. Third, there is a discordance between CEC and AREA for their correlations with other biomarkers. To the best of our knowledge, there was no study to investigate effects of CR on both CEC and AREA compared with nonexercise usual therapy in CAD patients. The results provide the effects of CR on functional properties of HDL and further support to CR for the secondary prevention. Table 5 shows limited studies that investigated completed the CR program. Although CEC and AREA were significantly correlated each other (ρ= 0.364, P = 0.002, n = 84 at baseline and ρ= 0.274, P = 0.020, n = 72 at follow-up), correlation coefficients between CEC or AREA and other variables were different. The AREA at baseline and follow-up were negatively correlated with age and positively correlated with exercise capacity, while the CEC at baseline and follow-up were significantly positively correlated with HDL-C. Both CEC and AREA were positively associated with apoA-I. AREA at baseline was negatively correlated to hsCRP. Neither CEC nor AREA correlated to LDL-C, non-HDL-C, apoB, Lp(a), and HbA1c. Both changes in CEC and AREA were significantly associated with those in HDL and apoA-I. Fig. 4 shows the correlation coefficients between percent changes in CEC, AREA, HDL-C, and apoA1 in whole patients. The changes in these biomarkers were significantly correlated with each other. On the other hand, lack of association between percent changes in CEC or AREA and those in Peak VO2, triglyceride, MDA-LDL, and hsCRP were observed. Cross-sectional studies reported that both HDL-C and CEC were significantly higher in athletes compared with non-athlete controls 34, 35) , and that both HDL-C and apoA-1 were significantly associated with CEC and Peak VO2 34) . With regard to PON1 activity and physical activity, both positive correlation [35] [36] [37] and lack of correlation 38) were reported. The former studies support the positive association between AREA and peak VO2 in the present study. Tomás et al. reported an opposite effect of exercise training on PONA according to PON1-192 polymorphism 39) . A recent report with Turkish national judoists showed that an anaerobic judo training increased significantly PONA, AREA, and HDL-C, and that interaction of PON1-192 polymorphism was seen in not AREA but PONA 33) . In addition to genetic factors, regulation of PON1 activity is affected by environmental factors such as anxiety 40) , oxidative stress 41) , and inflammation 42) . In contrast to the previous report 41) , the present study failed to show an association between AREA the effects of exercise training on quantity of HDL and HDL function (CEC and/or PON1) 13, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . These inconsistent results may be partially due to differences in studied population, HDL-C levels at baseline, exercise status, and concomitant therapy such as diet and medication. Among them, four studies compared both CEC and PON1 activity, and all these studies failed to show increases in HDL-C and apoA-1. CasellaFilho et al. reported that a 3-month aerobic exercise training increased both PONA and CEC without changes in BMI, in sedentary subjects with metabolic syndrome 24) . Sang et al. reported that exercise training increased PONA alone in patients with metabolic syndrome compared with non-exercise counterparts 26) . Aicher et al. reported that weight loss program significantly reduced both HDL-C and CEC, without changes in AREA in overweight or obese women 27) . In contrast, Králová Lesná et al. reported that a significant weight reduction was significantly associated with increases in CEC in young healthy obese women 28) . Fig. 3 . Effects of risk factor control and exercise capacity at follow-up period on CEC among patients in CR group. Data are expressed as mean±SD. The number in parenthesis indicates actual number of analyzed cases. Seven samples at baseline were collected in fasting-state at the beginning of CR. The others were collected immediate before the emergency coronary angiography on admission. Target controlled blood pressure are defined as ＜140 systolic and ＜90 diastolic. Target controlled HbA1c levels are defined as ＜7.0%. Target controlled lipid levels of LDL-C, non-HDL-C, HDL-C, and triglyceride are defined as ＜100, ＜130, ≥ 40, and ＜150 mg/dl, respectively. patients. Tang et al. reported that not PONA value but lower AREA predicted long-term cardiovascular risk in both primary and secondary prevention subjects although genetic determinants of PONA and AREA were not associated with cardiovascular risk. They showed that some single nucleotide polymorphisms were contrast association with PONA (positive) and AREA (negative), and that the relationship between AREA and its genetic determinants was lower than those with PONA 44) . These suggest that AREA differ from PONA, and we measured only AREA. Future studies are required to measure both AREA and MDA-LDL as surrogate marker for oxidative stress, while AREA at baseline was significantly inversely associated with hsCRP. Furthermore, Kameyama et al. reported that postprandial increases in AREA and postprandial decreases in PON-1 lactonase activities in healthy men 43) . The baseline blood samples were collected at non-fasting state on admission in 92% of patients, and AREAs at baseline in these patients were slightly higher compared with the AREA in fasting state at the beginning of the CR (756.2±170.2 vs 727.4±129.0, respectively). These various factors may attenuate the changes in AREA induced by CR in our significant increases in HDL-C and apoA-I were seen in only CR patients treated with pitavastatin or rosuvastatin, while significant increases in CEC were observed in CR patients, irrespective of the types of statins. The reasons for the increases in CEC by CR have not been elucidated clearly. As the majority of the patients in CR group achieved targets of BP and HbA1c, it is difficult to investigate whether risk factor control affect the present results. Tanaka et al. reported that a 4-week administration of high dose eicosapentaenoic acids increased CEC although HDL-C and serum AREA did not change in 21 patients with dyslipidemia 48) . The increases in CEC were observed even when we excluded the patients who took n-3 PUFA, ezetimibe, and ACE-I. In non-CR group, the patients did not want to participate supervised CR program, and other unmeasured factors may have affected the results. Anyway, whatever the mechanism, our results confirmed that CR could improve HDL function. Future prospective studies are required to investigate the mechanisms of effects of CR and usual therapy for ACS on CEC and AREA.
A cross-sectional study with 205 ACS patients and 100 healthy subjects showed that the significant and PONA, and evaluate effects of various factors on CEC, AREA, and PONA in a large population.
The ninety-nine percent of patients took statins during the follow-up period. A meta-analysis of 25 clinical trials including one study in Japan 45) showed that statin therapy was associated with a significant elevation of PONA and AREA 46) . However, this metaanalysis described that elevation of AREA following statin therapy varied in the type of statin. Significant effects were observed in trials with simvastatin and were not found in trials with atorvastatin and rosuvastatin 47) . Only one study from Miyamoto-Sasaki et al showed that 4-week treatment with 2 mg of pitavastatin significantly increased HDL-C by 9%, CEC by 8.6%, and AREA by 11% in 30 patients with dyslipidemia 45) . In the present study, no patient took simvastatin, and only nine patients took pitavastatin at follow-up. Nicholls et al. have reported that a 12-week statin monotherapy with 20 mg of atorvastatin, 10 mg of rosuvastatin or 40 mg of simvastatin significantly decreased CEC and preβ1 HDL compared with placebo in patients with dyslipidemia, and CEC at baseline was significantly correlated with HDL-C, apoA-I, and preβ1 HDL 47) . The present study showed that CEC and those in AREA. Both CEC and AREA were significantly associated with apoA-I rather than HDL-C. It has been reported that apoA-I is important for the stability and activity of PON1 on HDL 50) . A report of homozygous and heterozygous apoA-I deficiency showed that apoA-I is the major HDL component underlying both CEC and anti-oxidative activity 51) . correlation between CEC and PONA was positive in healthy subjects and inverted in ACS patients, and that no correlation between CEC and HDL-C in both groups, although both CEC and PONA were significantly lower in ACS patients than in healthy subjects 49) . The present study showed positive correlation between CEC and AREA, and between changes in anaerobic exercise, 2 hr/day, 6/w, 5 mo
HDL-C↑ PONA↑ AREA↑
ApoA-1 = apolipoprotein A-1; AREA = arylesterase activity; CAD = coronary artery disease; CEC = cholesterol efflux capacity; cont. = non-exercise control group; CVD = cardiovascular disease; d = day; DM = diabetes mellitus; erg = ergometer; F = female; hr = hour; HDL-C = HDL cholesterol; M = male; min = minute; mo = month; MS = metabolic syndrome; nonDM = non diabetes mellitus; PONA = paraoxonase activity; w = week; y = year; ↑= increase; ↓= decrease; → = no change. ＊ CEC was significantly increased when two females with lowest weight change were excluded.
HDL particle contains 2 to 5 molecules of apoA-I 52) and inflammation replaces apoA-I in HDL particle with serum amyloid A 53) . In contrast to apoB, serum apoA-I could not be reflected as HDL particle number. Thus, it is difficult to evaluate CEC per HDL particle. The present study suggests that CR improve individual CEC, and that apoA-I may serve as surrogate biomarkers of HDL function.
The major limitation of the present study is a single center retrospective analysis with small sample size particularly in female patients with ACS and patients in non-CR group. Therefore, our results should be confirmed by prospective studies with more sample size in future. This study is associated with several other limitations. First, heterogeneity of HDL and composition of proteins and lipids of HDL were not examined. Second, lecithin cholesterol acyltransferase, cholesterol ester transfer protein, hepatic lipase and endothelial lipase were not measured. These factors play important roles in HDL metabolism. Third, genetic polymorphisms of PON1 and/or anxiety state on AREA were not evaluated. Fourth, regular physical activity was not measured in all patients. Fifth, we did not measure PONA and PON1 protein concentration. These factors should be investigated in future studies.
Conclusion
The present study of ACS patients demonstrated three findings. First, five-month outpatient CR program significantly improved CEC despite of no changes in HDL-C. Second, increases in CEC were significantly correlated to increases in AREA, however. there is a discordance between CEC and AREA for their correlations with other biomarkers. Third, both CEC and AREA were significantly correlated with apoA-I rather than HDL-C. These results suggest that one of the beneficial effects of the comprehensive CR can increase functional HDL particles. Again, future prospective studies should be conducted to evaluate these issues in larger number of sample size.
